Type de présentation | Oral presentation |
Titre | Ruthenium Brachytherapy in eye tumors |
But | Between 2019 and 2013, 214 applications with Ruthenium brachytherapy in Leuven University Hospital. This study audits the indications, results, and the rates of local and distal metastases. |
Méthodes | Retrospective study |
Résultats | Of 214 applications, 25 were conjunctival melanomas, 11 squamous cell carcinomas, 3 metastases, 2 hemangiomas, and 1 sacroma. The other 172 were uveal melanomas. Different sizes of plaques were used: 92 CCA, 91 CCB, 26 COB (for juxtapapillary tumors) and 5 CCC. 111 right eyes, and 100 males. Mean age at diagnosis was 66 years. |
Conclusion | Ruthenium brachytherapy is a good and safe treatment for uveal and conjunctival melanomas, and can be very effective voor squamous cell carcinomas, large hemangiomas and metastases. |
Conflit d'intérêt | Non |
Nom | MISSOTTEN |
Initiales | G |
Institut | Jessa Oogkliniek Hasselt and University Hospitals Leuven |
Ville | Hasselt/Leuven |
Nom | Van Calster |
Initiales | J |
Institut | Leuven University Hospitals |
Ville | Leuven |